How Long Does RSV Immunity Last After Infection or Vaccination?

RSV immunity is remarkably short-lived compared to what most people expect from a viral infection. After a natural RSV infection, neutralizing antibodies in infants can fall back to pre-infection levels in roughly three months, and adults typically see a substantial decline within a year. Vaccines approved for older adults and pregnant individuals extend protection meaningfully, but even vaccinated immunity wanes, with efficacy dropping over successive RSV seasons. The picture is more complex than a single number can capture, because different parts of the immune system fade at different rates.

Why Natural RSV Immunity Fades So Quickly

Most viruses that cause repeated infections do so because they mutate quickly enough to dodge your existing antibodies. RSV can reinfect you even when it hasn’t changed much, which tells us something unusual about the immune response it triggers. A birth-cohort study that tracked neutralizing antibody levels in infants found that after a first RSV infection, antibody titers rose within about two weeks, peaked between two weeks and a month, and then fell back to pre-infection levels by roughly three months.¹ That is a strikingly fast decline. For context, antibodies after measles infection typically last decades.

Adults fare somewhat better, but not by a lot. A study of healthy adults who had confirmed RSV infections found that the average rate of antibody decline led to a fourfold or greater drop in titer within a year in three out of four people.² Those antibodies don’t disappear entirely, but they drop below the levels that meaningfully block infection. This helps explain why RSV reinfection is the norm across all age groups, not the exception.

Large surveillance data bear this out. In one U.S. analysis of children who had a first documented RSV infection, annual reinfection rates ran around 0.25% for hospitalizations and about 3.4% for outpatient cases, with reinfection rates declining as children got older and accumulated more exposures.³ A Kenyan birth-cohort study found that nearly two-thirds of enrolled children experienced at least one RSV infection, and almost half of those had two or more infections, with a handful having four or five.⁴ Prior infection did reduce the severity of subsequent episodes, but it clearly didn’t prevent them.

The Role of T Cells and Memory Beyond Antibodies

Antibody levels are the easiest thing to measure, so they dominate most durability discussions. But a growing body of research suggests that a different arm of the immune system, tissue-resident memory T cells in the lungs, plays an important role in limiting how sick RSV makes you, even when your antibodies have faded.

A human challenge study found that people who had higher numbers of RSV-specific CD8+ memory T cells in their airways before deliberate RSV exposure experienced fewer symptoms and lower viral loads, even though these T cells didn’t prevent infection outright.⁵ Animal studies have confirmed that these lung-resident T cells, when activated by RSV antigens, directly reduced viral replication.⁶

This split between infection and disease is important for understanding what “immunity” actually means with RSV. Your antibodies may drop too low to keep the virus from gaining a foothold. But your T cells, particularly the ones embedded in lung tissue, can limit viral spread and reduce the chance that infection escalates to pneumonia or bronchiolitis. This helps explain why adults get RSV repeatedly but usually experience it as a bad cold, while infants and older adults, whose T cell responses are either undeveloped or declining, face more severe illness.

Correlates of Protection and the Antibody Threshold Problem

Researchers have been trying for years to define a concrete antibody level that reliably predicts protection from RSV. This turns out to be difficult. A prospective cohort study found that higher binding and neutralizing antibody titers were associated with a lower risk of RSV illness, and this association was statistically significant in children but not clearly so in adults.⁷ Older work has attempted to set minimum protective thresholds for neutralizing antibodies, finding that people hospitalized with RSV had significantly lower antibody titers than those hospitalized for other reasons.⁸

The trouble is that antibody levels tell only part of the story. As noted above, cellular immunity and mucosal immune responses in the airways also contribute to protection, and these are harder to measure with a routine blood draw. This is why some immunocompromised patients show reasonable clinical protection from RSV vaccines despite underwhelming antibody responses. It also means that any single number quoted as a “protective threshold” should be treated as a rough guide rather than a hard line.

How Maternal Antibodies Protect Newborns

Babies are born with a supply of their mother’s antibodies, transferred across the placenta during the third trimester. For RSV, these maternal antibodies start declining almost immediately after birth. A study in coastal Kenya measured a half-life of about 36 days for maternally derived RSV-neutralizing antibodies, with a steady log-linear decline over the first six months of life.⁹ A study in Nepal found a similar rate of decay.¹⁰

Despite the rapid decline, maternal antibodies still provide meaningful protection against severe RSV during roughly the first six to seven months, particularly when the mother’s antibody levels were high at delivery.¹¹ This is the biological principle behind vaccinating pregnant women: if you can boost the mother’s antibodies before delivery, the baby arrives with a higher starting supply and stays above a protective threshold for longer.

Infant Protection Through Vaccines and Monoclonal Antibodies

Two approaches are now available to protect newborns and young infants from RSV, and their durability differs.

The maternal RSV vaccine (Abrysvo, a prefusion F protein vaccine given to pregnant women) showed roughly 80% efficacy in preventing severe RSV illness during the first 90 days after birth, dropping to about 69% over 180 days.¹² That decline mirrors the natural half-life of transferred antibodies: the baby is living off a finite supply that doesn’t get replenished. Modeling studies have estimated that if maternal RSV vaccination were implemented across lower-income countries, millions of hospitalizations and over a hundred thousand deaths could be prevented in infants under six months.¹³

The other approach is nirsevimab (Beyfortus), a monoclonal antibody given directly to the baby as a single injection. Unlike a vaccine, nirsevimab doesn’t train the baby’s own immune system; it simply delivers a large dose of a pre-made antibody engineered for an extended half-life.¹⁴ Clinical data show that neutralizing antibody levels after nirsevimab remained more than 50 times above baseline at about five months and were still roughly seven times above baseline at a full year.¹⁵ That long tail provides coverage well beyond a single RSV season for most infants. Current guidance generally recommends one dose before or during the infant’s first RSV season, without a second dose.

How Long Do Older Adult RSV Vaccines Last?

The RSV vaccines approved for adults 60 and older are the most straightforward case for answering “how long does it last?” because multi-season clinical trial data now exist.

GSK’s Arexvy (RSVPreF3 OA) was tested over three consecutive RSV seasons. A single dose showed about 67% efficacy against RSV-related lower respiratory tract disease over two seasons and roughly 63% cumulative efficacy over three seasons, with about 70% protection against severe disease persisting across those three years.^{16 17} Efficacy did decline season over season, but the protection against the most severe outcomes held up better than the protection against milder respiratory illness.

Moderna’s mRNA-based RSV vaccine (mRNA-1345) demonstrated about 84% efficacy against RSV-associated lower respiratory tract disease in its first-season data, though the median follow-up was only about four months, so long-term durability data are still being collected.¹⁸ Early first-season numbers often look higher because they capture the period when the immune response is strongest.

An important finding from the Arexvy trials: a booster dose given one year after the first dose did not clearly improve protection compared with a single dose alone.¹⁶ This is why current U.S. recommendations don’t call for annual revaccination. Whether a booster at a longer interval, say two or three years, might be beneficial is an open question that ongoing studies should clarify.

Why Older Adults Face Higher RSV Risk Despite a Lifetime of Exposure

It seems paradoxical: adults over 60 have been infected with RSV many times throughout their lives, yet they’re one of the groups most vulnerable to severe disease. A review of the evidence points to a combination of factors beyond just antibody waning: age-related changes in the lungs make mechanical defenses weaker, chronic diseases like heart failure and COPD amplify the inflammatory response, and the immune system itself becomes less effective with age in ways that go beyond simply having lower antibody titers.¹⁹ This helps explain why even older adults with detectable RSV antibodies can still develop serious disease. Their antibodies exist, but the rest of their immune machinery and their airways don’t support an effective response.

What Immunocompromised People Should Know

People with weakened immune systems, including transplant recipients and those on certain immunosuppressive medications, respond to RSV vaccines less robustly and less predictably. Seroconversion rates in transplant populations commonly range from about 30% to 60%, heavily influenced by how recently the transplant occurred and what medications the patient takes.²⁰ Despite those lower antibody responses, first-season vaccine effectiveness against hospitalization has still been estimated at roughly 65% to 75% in these groups, possibly because T cell responses can be preserved even when antibody production is impaired.²⁰

The durability picture, however, is less encouraging. Protection wanes faster in immunocompromised individuals than in those with healthy immune systems.²¹ In one study of immunosuppressed patients, antibody levels rose significantly by 12 weeks after vaccination, but only about 37% to 39% of participants reached conservative high-titer thresholds, and that proportion didn’t improve further out to six months.²² Many immunosuppressed individuals never achieve what researchers consider a robustly protective antibody level, which has prompted calls for investigating additional or modified dosing strategies for this group.

Why the Prefusion F Protein Matters for Durability

All currently approved RSV vaccines and nirsevimab target the RSV F protein in its “prefusion” shape, the form the protein takes before it fuses with a human cell. This design choice wasn’t obvious, and getting it wrong set the field back decades.

In the 1960s, a formalin-inactivated RSV vaccine was tested in infants and toddlers. Instead of protecting them, it primed their immune systems in a way that led to more severe disease when they encountered wild RSV. Two children died.²³ Later analysis revealed that the inactivation process had destroyed the prefusion shape of the F protein, so the vaccine generated antibodies that bound to F but were poor at actually neutralizing the virus or blocking fusion.²⁴ The immune response was robust in quantity but functionally useless, and it skewed toward inflammatory pathways that worsened disease upon actual infection.

Modern vaccines use a stabilized prefusion F protein, and the difference in antibody quality is dramatic. In head-to-head comparisons, prefusion F vaccines elicited antibodies that were substantially more potent at neutralizing both RSV A and RSV B subtypes, and they preferentially activated the memory B cells most likely to produce high-quality neutralizing antibodies upon re-exposure.²⁵ This is one reason the newer vaccines show durability measured in seasons rather than weeks: they generate the right kind of antibodies, not just a large volume of mediocre ones.

RSV A Versus RSV B and What It Means for Lasting Protection

RSV circulates as two major subtypes, A and B, and they co-circulate in most seasons with shifting dominance. Some vaccines include antigens from both subtypes (bivalent), while others target only one. Clinical data from bivalent vaccine trials show strong efficacy against both subtypes, but monovalent vaccine studies suggest that cross-protection against RSV B may wane more quickly than protection against RSV A.²⁶ The three-season Arexvy data also broke out results by subtype and showed roughly similar efficacy against both, though point estimates were slightly lower for RSV B.¹⁷

For practical purposes, this means the durability of your vaccine-induced protection could partly depend on which subtype is dominant in a given season. In a year when RSV B dominates, protection from a monovalent vaccine might look weaker than in an RSV A-heavy year. This subtype-specific waning is an active area of investigation and could eventually influence whether annual reformulation, similar to what we do for flu, becomes part of RSV vaccination strategy.

What the Pandemic Lockdowns Taught Us About RSV Immunity Maintenance

An unplanned natural experiment occurred during COVID-19 lockdowns. With schools and daycares closed and people staying home, RSV effectively stopped circulating for more than a year in many countries. When it came back, several countries saw unusually large and out-of-season RSV surges that hit older children harder than expected. A systematic review found that RSV antibody levels declined measurably during the period of reduced circulation, and the drop appeared to be larger in children than in adults.²⁷ More infants who had never encountered RSV at all were present in the population, creating a larger pool of completely naive immune systems.

Interestingly, influenza antibody levels did not decline significantly during the same period despite similar drops in flu circulation.²⁷ This contrast highlights something specific about RSV: population-level immunity depends on repeated re-exposure in a way that influenza immunity apparently does not. It reinforces the point that natural RSV immunity is uniquely leaky and short-lived. Regular seasonal contact with the virus acts as a kind of ongoing booster for the population, and when that booster disappears, immunity drops fast enough to cause visible consequences within a year or two.